Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries.
[BACKGROUND] Breast cancer is the most common malignancy among women, posing major health, social, and economic challenges worldwide.
APA
Gu H, Wang R, et al. (2026). Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries.. Chinese medical journal, 139(3), 404-414. https://doi.org/10.1097/CM9.0000000000003921
MLA
Gu H, et al.. "Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries.." Chinese medical journal, vol. 139, no. 3, 2026, pp. 404-414.
PMID
41473983
Abstract
[BACKGROUND] Breast cancer is the most common malignancy among women, posing major health, social, and economic challenges worldwide. This study analyzed global breast cancer incidence and mortality in 2022 using Global Cancer Observatory (GLOBOCAN) 2022 data and projected the disease burden to 2050.
[METHODS] Breast cancer incidence and mortality were categorized by region and age. Correlations between age-standardized rates (ASRs) and the Human Development Index (HDI) were assessed using Spearman's rank correlation coefficient (ρ). Future burden estimates for 2050 were projected based on current trends.
[RESULTS] In 2022, approximately 2.30 million new breast cancer cases and 666,103 deaths were reported globally. Age-specific patterns of breast cancer incidence and mortality differed across development HDI levels with incidence peaking at ages 45-69 years and mortality at ages 50-≥85 years across HDI levels. The proportion of cases and deaths among women aged ≥50 years relative to those aged ≤49 years increased with HDI, ranging from 79% vs . 21% for incidence and 90% vs . 10% for deaths in very high HDI countries to 51% vs . 49% and 59% vs . 41% in low HDI countries. HDI showed strong positive correlations with age-standardized incidence rates (ρ = 0.773), period incidence rates (ρ = 0.958), and period mortality rates (ρ = 0.907), and a negative correlation with mortality-to-incidence ratios (ρ = -0.817). Projections indicate that by 2050, breast cancer cases may rise to 3.55 million and deaths to 1.14 million if current patterns continue.
[CONCLUSIONS] Breast cancer remains a major global health concern. Strengthening prevention, early detection, and therapeutic strategies is essential to reduce incidence, improve survival, and alleviate its global burden.
[METHODS] Breast cancer incidence and mortality were categorized by region and age. Correlations between age-standardized rates (ASRs) and the Human Development Index (HDI) were assessed using Spearman's rank correlation coefficient (ρ). Future burden estimates for 2050 were projected based on current trends.
[RESULTS] In 2022, approximately 2.30 million new breast cancer cases and 666,103 deaths were reported globally. Age-specific patterns of breast cancer incidence and mortality differed across development HDI levels with incidence peaking at ages 45-69 years and mortality at ages 50-≥85 years across HDI levels. The proportion of cases and deaths among women aged ≥50 years relative to those aged ≤49 years increased with HDI, ranging from 79% vs . 21% for incidence and 90% vs . 10% for deaths in very high HDI countries to 51% vs . 49% and 59% vs . 41% in low HDI countries. HDI showed strong positive correlations with age-standardized incidence rates (ρ = 0.773), period incidence rates (ρ = 0.958), and period mortality rates (ρ = 0.907), and a negative correlation with mortality-to-incidence ratios (ρ = -0.817). Projections indicate that by 2050, breast cancer cases may rise to 3.55 million and deaths to 1.14 million if current patterns continue.
[CONCLUSIONS] Breast cancer remains a major global health concern. Strengthening prevention, early detection, and therapeutic strategies is essential to reduce incidence, improve survival, and alleviate its global burden.
MeSH Terms
Humans; Breast Neoplasms; Female; Incidence; Middle Aged; Aged; Adult; Aged, 80 and over; Global Health; Global Burden of Disease
같은 제1저자의 인용 많은 논문 (5)
- The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons.
- FAPα Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
- Macrocyclic Pyclen-Based Hybrid Nanoprobes for Magnetic Resonance Imaging of Sentinel Lymph Node Metastasis.
- Nonionotropic action of an acid-sensing ion channel inhibits leukemogenesis in the acidic bone marrow niche.
- CUL4B regulates thyroid cancer differentiation and treatment sensitivity by ubiquitinating ARID1A.